Compare PMAX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | LTRN |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | Hong Kong | United States |
| Employees | 53 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 22.2M |
| IPO Year | N/A | 2020 |
| Metric | PMAX | LTRN |
|---|---|---|
| Price | $3.37 | $2.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 213.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.11 |
| 52 Week High | $5.20 | $5.74 |
| Indicator | PMAX | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 57.79 |
| Support Level | $1.90 | $1.96 |
| Resistance Level | $5.01 | $3.67 |
| Average True Range (ATR) | 0.62 | 0.25 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 50.49 | 73.39 |
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.